BBY Updates Cynata Research Coverage

Melbourne, Australia, 20 February 2015: Australian stem cell and regenerative medicine company Cynata Therapeutics (ASX: CYP) announced today that BBY Ltd has published an updated equity research coverage.

A synopsis of the BBY Ltd report can be viewed on Cynata's website at www.cynata.com/news/

Further inquiries:

Dr Ross Macdonald	Dr Stewart Washer	Emma Power
Chief Executive Officer	Executive Chairman	Monsoon Communications
Tel: 0412 119343	Tel: 0418 288 212	Tel: 0419 149 525
ross.macdonald@cynata.com	stewart.washer@cynata.com	emmap@monsoon.com.au

Kirin Smith	Sean Leous
PCG Advisory Investor Contact	PCG Advisory Media Contact
+ 1 646-863-6519	+1 646-863-8998
ksmith@pcgadvisory.com	sleous@pcgadvisory.com

About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company developing and commercialising a novel method for producing scalable quantities of mesenchymal stem cells for therapeutic application. The platform technology, Cymerus™, originates from the University of Wisconsin-Madison, a facility that is widely recognised as a world leader in stem cell research. Cynata's proprietary Cymerus™ technology seeks to address a critical shortcoming in existing production methods of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ achieves this by producing a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA technology provides a source of MSCs that are independent of donor limitations and provide a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. The Cymerus™ technology has great potential to create a new standard globally in stem cell therapeutics, with a novel manufacturing technology and an important competitive position.